[HTML][HTML] Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions
Fibrotic diseases take a very heavy toll in terms of morbidity and mortality equal to or even
greater than that caused by metastatic cancer. In this review, we examine the pathogenesis
of fibrotic diseases, mainly addressing triggers for induction, processes that lead to
progression, therapies and therapeutic trials. For the most part, we have focused on two
fibrotic diseases with lung involvement, idiopathic pulmonary fibrosis, in which the
contribution of inflammatory mechanisms may be secondary to non-immune triggers, and …
greater than that caused by metastatic cancer. In this review, we examine the pathogenesis
of fibrotic diseases, mainly addressing triggers for induction, processes that lead to
progression, therapies and therapeutic trials. For the most part, we have focused on two
fibrotic diseases with lung involvement, idiopathic pulmonary fibrosis, in which the
contribution of inflammatory mechanisms may be secondary to non-immune triggers, and …
Abstract
Fibrotic diseases take a very heavy toll in terms of morbidity and mortality equal to or even greater than that caused by metastatic cancer. In this review, we examine the pathogenesis of fibrotic diseases, mainly addressing triggers for induction, processes that lead to progression, therapies and therapeutic trials. For the most part, we have focused on two fibrotic diseases with lung involvement, idiopathic pulmonary fibrosis, in which the contribution of inflammatory mechanisms may be secondary to non-immune triggers, and systemic sclerosis in which the contribution of adaptive immunity may be predominant.
Springer